Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,519
  • Shares Outstanding, K 86,422
  • Annual Sales, $ 15,620 K
  • Annual Income, $ -67,660 K
  • 60-Month Beta 2.82
  • Price/Sales 31.42
  • Price/Cash Flow N/A
  • Price/Book 9.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.74 +13.71%
on 10/24/19
6.22 -13.34%
on 11/08/19
+0.54 (+11.13%)
since 10/18/19
3-Month
3.69 +46.07%
on 08/21/19
6.22 -13.34%
on 11/08/19
+1.72 (+46.87%)
since 08/20/19
52-Week
3.42 +57.60%
on 08/20/19
6.31 -14.58%
on 07/01/19
+0.33 (+6.52%)
since 11/20/18

Most Recent Stories

More News
Progenics Pharm Shares Up 20.8% Since SmarTrend's Buy Recommendation (PGNX)

SmarTrend identified an Uptrend for Progenics Pharm (NASDAQ:PGNX) on September 5th, 2019 at $4.66. In approximately 2 months, Progenics Pharm has returned 20.82% as of today's recent price of $5.63.

PGNX : 5.39 (-6.75%)
Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ("Progenics" or the "Company"), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,...

PGNX : 5.39 (-6.75%)
Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board

Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ:PGNX), comprised...

PGNX : 5.39 (-6.75%)
Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates

Progenics (PGNX) delivered earnings and revenue surprises of 18.52% and -20.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PGNX : 5.39 (-6.75%)
Progenics: 3Q Earnings Snapshot

NEW YORK (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $18.8 million in its third quarter.

PGNX : 5.39 (-6.75%)
Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for

Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PGNX : 5.39 (-6.75%)
Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter 2019.

PGNX : 5.39 (-6.75%)
Progenics Reminds Shareholders that November 17 is the True Deadline for Velan's Consent Solicitation

Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan

PGNX : 5.39 (-6.75%)
Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan's Nominees Control of the Board

November 17 is the Only Deadline for Velan's Consent Solicitation

PGNX : 5.39 (-6.75%)
Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board

--Glass Lewis Recommends Stockholders Vote FOR Dr. Gerard Ber, Dr. Eric Ende, Heinz Mausli and David Mims to Constitute Majority of Progenics Board and Highlights Concern with Lantheus Transaction

PGNX : 5.39 (-6.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PGNX with:

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

2nd Resistance Point 6.02
1st Resistance Point 5.70
Last Price 5.39
1st Support Level 5.21
2nd Support Level 5.03

See More

52-Week High 6.31
Last Price 5.39
Fibonacci 61.8% 5.21
Fibonacci 50% 4.86
Fibonacci 38.2% 4.52
52-Week Low 3.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar